2024-02-01 07:11:27
In the field of triple-negative breast cancer (TNBC), the ongoing FUTURE-SUPER study conducted at Fudan University Shanghai Cancer Center has taken a revolutionary step. The Phase II, open-label, randomized, controlled trial aims to redefine TNBC treatment strategies based on molecular subtyping. The first data has now been published in the renowned journal The Lancet Oncology published.
ST.art/AdobeStock
TNBC exhibits great heterogeneity in underlying molecular drivers as well as immune features and is therefore still difficult to treat. The FUTURE-SUPER study is investigating whether targeted treatment leads to an advantage for patients depending on the subtype of TNBC. The efficacy and safety of subtyping-based therapy in the first-line treatment of metastatic or relapsed TNBC were evaluated.
The study included 139 eligible participants aged 18–70 years with untreated metastatic or relapsed TNBC. Participants were carefully divided into five cohorts based on molecular subtypes and genomic biomarkers. These subtypes include Luminal Androgen Receptor (LAR), Immunomodulatory, Basal-Like Immune-Suppressed (BLIS), and Mesenchymal-Like (MES).
To view the content you must log in or register.
#Breakthrough #treatment #triplenegative #breast #cancer